MSB 7.69% $1.19 mesoblast limited

Bell Potter valuation, page-26

  1. 3,839 Posts.
    lightbulb Created with Sketch. 1307
    Cato


    I'm sorry but none of these you think are part of the end point;


    b) the end point was dimish the number of fatalities and accelerate the chances of transplant.


    Were Primary endpoints for the trial.  None of those had to be achieved for the trial to be successful.


 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.